PRODUCTION OF SOLUBLE HUMAN T CELL RECEPTOR CHAINS

可溶性人类 T 细胞受体链的生产

• 批准号: 2867960
• 负责人: Daniel P. Gold
• 金额: $ 10万
• 依托单位: TERA BIOTECHNOLOGY CORPORATION
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-04-19 至 2000-04-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2867960
• 关键词: T cell receptor; T lymphocyte; active immunization; antigen presenting cell; biomarker; cell line; dendritic cells; drug screening /evaluation; immunotherapy; laboratory mouse; molecular cloning; vaccine development

DESCRIPTION: (Adapted from the applicant's abstract) T-cell malignancies account for 15% of all lymphomas and current treatments do not usually yield significant long-term remission. The applicants propose to treat T-cell lymphoma by inducing a specific cellular immune response to "reject" only the certain proliferating T-cells. The Holy Grail of cancer immunotherapy is the identification of specific tumor markers that can be used to teach the immune system to remove the undesired population of cells while leaving other cells intact. They believe that a T-cell receptor should act as a tumor marker for a particular T-cell lymphoma. If sufficient quantities of soluble T-cell receptor were available then treatment of lymphoma by vaccination might be feasible. However, T-cell receptors are not naturally expressed in soluble form. The applicants propose to solve this problem by producing recombinant soluble T-cell receptor chains in insect cells. In Phase I they will test the feasibility of this therapeutic approach in an animal model. They will pulse autologous professional antigen presenting cells with recombinant mouse T-cell receptor beta chain ex vivo ant transfer the treated cells into mice prior to challenge with a tumorigenic T-cell line. If successful, they will extend their studies to human T-cell receptors in Phase II and clinical trials in Phase III. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：（改编自申请人摘要）t细胞恶性肿瘤